Three Specialists Offer Outlook on Employing Pomalidomide in Multiple Myeloma

Christina Izzo
Published: Tuesday, Nov 04, 2014
Dr. Noopur Raje

Noopur Raje, MD

As therapy options for patients with relapsed or refractory multiple myeloma have expanded in recent years, so have clinical considerations about how best to incorporate new agents into the treatment paradigm.

Three experts in multiple myeloma tackled questions about integrating pomalidomide (Pomalyst) into the management of patients as part of an OncLive Insights video series program on multiple myeloma. Pomalidomide, which the FDA approved in 2013, is the third generation of the immunomodulatory drugs (IMiDs) that have long been employed in combination therapies for the malignancy.

Participating in the OncLive Insights program were Noopur Raje, MD, director of the Multiple Myeloma Program at Massachusetts General Hospital; Sagar Lonial, MD, vice chair of Clinical Affairs in the Department of Hematology and Medical Oncology at Emory University School of Medicine; and Ann McNeill, RN, MSN, an advance practice nurse specializing in multiple myeloma at John Theurer Cancer Center.

OncLive: When would you incorporate pomalidomide?

Noopur Raje: If you look at the pomalidomide label, you can use pomalidomide if you’ve seen lenalidomide and a proteasome inhibitor like bortezomib before. A lot of the trials had enriched for patients who were refractory to lenalidomide and still responded to pomalidomide.  For example, if you look at MM-003, which actually got pomalidomide its approval in Europe, 75% of those patients were even refractory to bortezomib [Lancet Oncol. 2013;14(11):1055-1066].

So, certainly, in refractory patients, pomalidomide is a great drug. But, even so, if you’ve seen lenalidomide and bortezomib and have gotten maximal benefit out of that, I think going to pomalidomide is perfectly reasonable.

Pomalidomide in combination with dexamethasone is generally very well tolerated. And what we’ve learned with the IMiDs is that as we’ve gone from thalidomide to lenalidomide and now pomalidomide we’ve gotten better at managing the toxicities but also more so, I do think the toxicity profile has improved with the IMiDs.

When we first starting using thalidomide, we saw a lot of neuropathy. We saw a lot of constipation, and, at that time, we were using much higher doses. When we went to lenalidomide we saw a little bit of neuropathy, not a lot of constipation, and if you look at the doses we’re using, it goes to speak to the potency of these drugs. We started with 100 mg and 200 mg on thalidomide. Lenalidomide is 25 mg, and now with pomalidomide we’re using 4 mg, suggesting that we’re getting to more potent compounds which are a little more specific, and some of the toxicities that you see may in fact be off-target toxicities.

So coming to pomalidomide, it’s generally extremely well tolerated. The big toxicity that we encounter with the pomalidomide is myelosuppression. Even with skin rashes, which are a little more common with lenalidomide, about 20% to 25% of people will have the skin rashes associated with lenalidomide. You don’t see that same incidence with pomalidomide.

Neuropathy is seen, but, again, it’s much lower with pomalidomide. It’s very convenient because it’s oral and most of us start off using it at 4 mg, and depending n how patients are doing, you can always dose adjust.

How do you use pomalidomide? And it what line do you find it most effective?

Sagar Lonial: Pomalidomide is a drug that we’ve used a fair amount in the relapsed and refractory setting. Again, it tends to be in a lenalidomide-resistant patient population, and the advantage of pomalidomide is that it’s a pill. Patients can take it and come back and see you once a month or twice a month, depending upon their blood counts, and it’s a relatively straightforward regimen to use.

In the refractory setting, when do you incorporate an agent like pomalidomide or carfilzomib?

Ann McNeil: Those two drugs are the two newest agents that have been FDA approved for myeloma, and we use them in the relapsed/refractory setting. So both of these drugs are used in very specific indications, a very specific patient population.

These are patients who have had prior therapies. They have seen bortezomib in their past treatment history. They have seen an IMiD. For pomalidomide, they have had to have seen lenalidomide and they are refractory to their last treatment option. So they are either progressing right through that treatment or we stopped treatment for some reason, and within 60 days they have evidence of disease progression. They are considered refractory, and that’s when we would consider using either of those agents in that patient population.

What are some of the common toxicities a patient encounters on pomalidomide and how you handle those?


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x